Investment
Features
FeesSafety
Academy
More
Pluang+

Compare YieldMax AMD Option Income Strategy ETF (AMDY) vs Illumina, Inc. (ILMN) Price & Performance

YieldMax AMD Option Income Strategy ETFTrade
Illumina, Inc.Trade

Price performance (Past 24H)

Key statistics

YieldMax AMD Option Income Strategy ETF vs Illumina, Inc. — how do they compare? YieldMax AMD Option Income Strategy ETF trades at $45.9, while Illumina, Inc. trades at $191.57 (market cap $29.12B). The key difference: Illumina, Inc. is trading nearer its 52-week high, YieldMax AMD Option Income Strategy ETF nearer its low. Which is the better fit depends on your goals.

AMDYILMN
Sector
Income / Options OverlayHealth
52-Week High
$59.52$205.10
52-Week Low
$29.80$91.00
Market Cap
$29.12B
Enterprise Value
$30.48B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

YieldMax AMD Option Income Strategy ETF

No Aura AI signal available yet.

Illumina, Inc.

Illumina (ILMN) trades at $191.32, down 0.25% on the day, with a bullish earnings trend after beating Q2 2026 estimates. The stock shows strong profitability with a net margin of 18.34% and positive cash flow, though technical indicators signal near-term bearish pressure. Recent news highlights institutional buying and AI partnerships boosting growth prospects.

Outlook remains positive with a consensus price target of $201.58, offering ~5% upside, supported by solid fundamentals and analyst optimism. Risks include high valuation multiples and competitive pressures in genomics. The stock presents a growth opportunity with manageable near-term volatility.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About YieldMax AMD Option Income Strategy ETF

AMDY is an active ETF that seeks to generate weekly income by selling call options on AMD stock. It aims to provide investors with high yield while maintaining exposure to the price movements of Advanced Micro Devices.

Read more on AMDY

About Illumina, Inc.

Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.

Read more on ILMN